✦ LIBER ✦

A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab

✍ Scribed by Mitchell, Paul

Book ID: 120347420
Publisher: Informa plc
Year: 2011
Tongue: English
Weight: 259 KB
Volume: 27
Category: Article
ISSN: 0300-7995
DOI: 10.1185/03007995.2011.585394

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of Ranibizumab and Bevacizuma

Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol

✍ Berg, Karina; Pedersen, Terje R.; Sandvik, Leiv; Bragadóttir, Ragnheiður 📂 Article 📅 2015 🏛 Elsevier Science 🌐 English ⚖ 500 KB

Safety and Efficacy of a Flexible Dosing

Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular Degeneration: The SUSTAIN Study

✍ Frank G. Holz; Winfried Amoaku; Juan Donate; Robyn H. Guymer; Ulrich Kellner; Re 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 687 KB

PSS11 Ranibizumab and Bevacizumab for th

PSS11 Ranibizumab and Bevacizumab for the Treatment of Age-related Macular Degeneration: A Systematic Review and Economic Evaluation

✍ Martinez Ferez, I.M.; Flores Moreno, S. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Vascular disrupting agent for neovascula

Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate

✍ Ibrahim, Mohamed A; Do, Diana V; Sepah, Yasir J; Shah, Syed M; Van Anden, Elizab 📂 Article 📅 2013 🏛 Springer (Biomed Central Ltd.) 🌐 English ⚖ 399 KB

A single-arm, investigator-initiated stu

A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis

✍ Singh, R. P.; Srivastava, S.; Ehlers, J. P.; Bedi, R.; Schachat, A. P.; Kaiser, 📂 Article 📅 2014 🏛 BMJ Publishing Group 🌐 English ⚖ 992 KB

The safety of using anti-VEGF: Is there

The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273–1279

✍ David Wong; Antonia M. Joussen 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 68 KB